Baldwin Wealth Partners LLC MA Sells 5,300 Shares of Edwards Lifesciences Co. (NYSE:EW)

Baldwin Wealth Partners LLC MA cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 43.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 6,988 shares of the medical research company’s stock after selling 5,300 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Edwards Lifesciences were worth $517,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of EW. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter worth about $30,000. Prospera Private Wealth LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC grew its stake in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. Peoples Bank KS acquired a new position in Edwards Lifesciences during the third quarter worth $40,000. Finally, Roble Belko & Company Inc bought a new stake in Edwards Lifesciences during the fourth quarter worth $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent analyst reports. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective for the company. in a research report on Thursday, January 16th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. The Goldman Sachs Group increased their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Finally, Barclays lifted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $78.48.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock valued at $2,195,180 over the last three months. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Down 0.2 %

EW stock opened at $68.88 on Monday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The business has a 50-day simple moving average of $72.33 and a 200 day simple moving average of $70.36. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market cap of $40.63 billion, a PE ratio of 9.94, a price-to-earnings-growth ratio of 3.54 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.59 EPS. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.